相似文献
1
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
Nat Cancer. 2024 Oct;5(10):1459-1464. doi: 10.1038/s43018-024-00818-w. Epub 2024 Aug 26.
2
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
3
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
J Cancer Res Clin Oncol. 2021 Jan;147(1):205-212. doi: 10.1007/s00432-020-03323-6. Epub 2020 Jul 18.
4
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Health Technol Assess. 2011 Dec;15(41):1-204. doi: 10.3310/hta15410.
5
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.
Adv Ther. 2025 May 12. doi: 10.1007/s12325-025-03205-8.
6
NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.
Blood. 2024 Sep 19;144(12):1271-1283. doi: 10.1182/blood.2023023529.
7
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.
8
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Expert Rev Hematol. 2024 Apr-May;17(4-5):127-134. doi: 10.1080/17474086.2024.2326219. Epub 2024 Mar 5.
9
TIGIT blockade improves anti-Mycobacterium tuberculosis immunity.
PLoS Pathog. 2025 Jun 17;21(6):e1013228. doi: 10.1371/journal.ppat.1013228. eCollection 2025 Jun.
10
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.
Oncoimmunology. 2025 Dec;14(1):2529632. doi: 10.1080/2162402X.2025.2529632. Epub 2025 Jul 12.
引用本文的文献
1
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.
Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02766-5.
2
T Cells Dysfunction in Multiple Myeloma.
Immunotargets Ther. 2025 Sep 11;14:997-1014. doi: 10.2147/ITT.S534784. eCollection 2025.
3
Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications.
MedComm (2020). 2025 Sep 14;6(9):e70387. doi: 10.1002/mco2.70387. eCollection 2025 Sep.
4
A comeback for checkpoint inhibition in multiple myeloma.
Nat Cancer. 2024 Oct;5(10):1449-1451. doi: 10.1038/s43018-024-00803-3.
本文引用的文献
1
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13.
2
PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients.
Eur J Med Res. 2022 Dec 19;27(1):296. doi: 10.1186/s40001-022-00923-5.
3
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
J Clin Invest. 2023 Feb 15;133(4):e157907. doi: 10.1172/JCI157907.
4
Immune checkpoint therapy: Forging ahead.
Sci Transl Med. 2022 Nov 9;14(670):eadf2947. doi: 10.1126/scitranslmed.adf2947.
5
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.
Am J Hematol. 2023 Mar;98 Suppl 2(Suppl 2):S4-S12. doi: 10.1002/ajh.26752. Epub 2022 Oct 24.
6
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12.
7
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.
Nat Cancer. 2020 Jul;1(7):681-691. doi: 10.1038/s43018-020-0075-x. Epub 2020 Jun 22.
8
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
Biomedicines. 2021 Sep 21;9(9):1277. doi: 10.3390/biomedicines9091277.
9
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
JCI Insight. 2020 Jun 18;5(12):129353. doi: 10.1172/jci.insight.129353.
10
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4PD-1 Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.
Clin Cancer Res. 2020 Jul 1;26(13):3443-3454. doi: 10.1158/1078-0432.CCR-19-1714. Epub 2020 Mar 27.
Zotero 插件